It is also true that T2s that have lost most of their beta cell function may also suffer from the same deficiency of amylin. I actually believe that Symlin treatment may help some T2s as well. We often break out in fractions thinking that there are very different types of diabetes meriting different treatment, but in fact we are often very much the same. I would encourage the FDA to increasingly consider how evidence that a treatment works for T2 may provide strong evidence that it also works for T1 and vice versa.
